Osman İlhami ÖZCEBE, Nilgün ATAKAN, Ali ALKAN, Burak UZ, Hakan GÖKER

Rash associated with Pregabalin: A case report

Kırksekiz yaşında ve 2 aydır nöropati tedavisi için 300mg/gün oral yolla pregabalin kullanan erkek hasta, ekstremiteler ve lomber bölgesinde eritematöz, makülopapüler döküntü şikayeti ile başvurdu. Naranjo olasılık skalası döküntü ve pregabalin kullanımı arasında muhtemel bir ilişkiyi gösterdi. Pregabalin tedavisi kesilerek, antihistaminik tedavi, oral metilprednizolon ve topical steroidli krem başlandı. Tedavinin kesilmesinden 1 hafta sonra döküntü neredeyse tamamen düzeldi. Pregabalin ilişkili döküntü faz 3 klinik çalışmalarda nadiren rapor edilmiştir. Prega- balin kullanımına eşlik eden döküntü daha önce yalnızcabir vaka raporunda sunulmuştur. Pregabalin ilişkili döküntünün mekanizması tam olarak anlaşılamamıştır. Düşük dozlarda pregabalin tedavisine başlamak ve doz artımınıyavaş yapmak yan etki insidansını azaltabilir.

Pregabalin ilişkili döküntü: Olgu sunumu

A 48-year-old man with erythematous, maculopapularrash localized to his extremities and lumbar region thathe had been receiving oral pregabalin 300 mg per day for2 months to treat his neuropathy was applied. The Naranjo probability scale indicates a probable relationship between the development of rash and use of pregabalin byour patient. Pregabalin was discontinued and antihistaminic treatment, oral methyprednisolone and topical steroid cream were given to treat the rash. The rash almostcompletely resolved one week after pregabalin was dis-continued. Pregabalin-induced rash was rarely reportedin Phase 3 clinical trials, and there is currently only oneavailable report on the development of a rash coincidingwith the use of pregabalin. No clear mechanisms reportedfor rash associated with pregabalin. It is usually recommended to start pregabalin with low doses and slow increases might prevent the incidence of side effects.

PDF

___

1. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805- 1815.
2. Mula M, Pini S, Cassano GB. The role of anticonvul- sant drugs in anxiety disorders: a critical review of the evi-dence. J Clin Psychopharmacol 2007;27:263-272.
3. Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008;1:561-562.
4. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-1709.
5. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-1873.
6. Smith TL, Baldwin A, Cunningham LL Jr, et al. Rash Associated with Pregabalin Use. Ann Pharmacother 2008;42:1899-1902.
7. Pushkin R, Frassetto L, Tsourounis C, et al. Improving the reporting of adverse drug reactions in the hospital set-ting. Postgrad Med 2010;122:154-164.
8. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-1365.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
10. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug- induced skin, nail and hair disorders. Drug Saf 2007;30:1011-1030.
11. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with prega- balin: A randomized, placebo-controlled trial. J Pain 2005;6:253-260.
12. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104- 2110.
13. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double blind, placebo-controlled trial. Pain 2004;110:628-638.
14. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol 2008;8:33.
15. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45:13-